Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Eiger BioPharmaceuticals, Inc. (EIGR) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/20/2022 8-K Quarterly results
01/07/2020 8-K Resignation/termination of a director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : January 6, 2020 EIGER BIOPHARMACEUTICALS, INC. Delaware 001-36183 33-0971591 Eiger BioPharmaceuticals, Inc. 2155 Park Blvd. Palo Alto, California 94306 272-6138 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement comm..."
06/02/2015 8-K Resignation/termination of a director

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy